Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Drug Therapy, Combination"" wg kryterium: Temat


Tytuł:
Efficacy and safety of Tengfu Jiangya tablet combined with valsartan/amlodipine in the treatment of stage 2 hypertension: study protocol for a randomized controlled trial.
Autorzy:
Wang Y; Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250011, Shandong, China.
Hua Z; Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250011, Shandong, China.
Chen W; Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250011, Shandong, China.
Zhu Y; Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250011, Shandong, China.
Li Y; Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250011, Shandong, China. .; Shandong University of Traditional Chinese Medicine, Jinan, 250355, Shandong, China. .
Pokaż więcej
Źródło:
Trials [Trials] 2022 Feb 22; Vol. 23 (1), pp. 171. Date of Electronic Publication: 2022 Feb 22.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Drug Therapy, Combination*/adverse effects
Drugs, Chinese Herbal*/adverse effects
Hypertension*/drug therapy
Amlodipine/adverse effects ; Antihypertensive Agents/adverse effects ; Blood Pressure ; Double-Blind Method ; Humans ; Multicenter Studies as Topic ; Randomized Controlled Trials as Topic ; Tablets ; Valsartan/adverse effects
Czasopismo naukowe
Tytuł:
Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients.
Autorzy:
van de Laar CJ; Transparency in Healthcare BV, Hengelo, the Netherlands.
Janssen CA; Transparency in Healthcare BV, Hengelo, the Netherlands.; Department of Psychology, Health & Technology, University of Twente, Enschede, The Netherlands.
Janssen M; Department of Rheumatology, VieCuri Medical Center, Venlo, The Netherlands.
Oude Voshaar MAH; Transparency in Healthcare BV, Hengelo, the Netherlands.; Department of Psychology, Health & Technology, University of Twente, Enschede, The Netherlands.
Al MJ; Institute for Medical Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
van de Laar MAFJ; Transparency in Healthcare BV, Hengelo, the Netherlands.; Department of Psychology, Health & Technology, University of Twente, Enschede, The Netherlands.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2022 Jan 28; Vol. 17 (1), pp. e0261940. Date of Electronic Publication: 2022 Jan 28 (Print Publication: 2022).
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Drug Therapy, Combination*
Gout*/blood
Gout*/drug therapy
Gout*/economics
Gout Suppressants*/economics
Gout Suppressants*/therapeutic use
Models, Economic*
Uric Acid/*blood
Anti-Inflammatory Agents/economics ; Anti-Inflammatory Agents/therapeutic use ; Cost-Benefit Analysis ; Costs and Cost Analysis ; Humans
Czasopismo naukowe
Tytuł:
Prevalence and predictors of glucose metabolism disorders among People Living with HIV on combination antiretroviral therapy.
Autorzy:
Tadesse WT; Department of Pharmacology and Clinical Pharmacology, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Adankie BT; Department of Medical Microbiology, School of Medicine, St. Paul Specialized Hospital Millennium Medical College, Addis Ababa, Ethiopia.
Shibeshi W; Department of Pharmacology and Clinical Pharmacology, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Amogne W; Department of Internal Medicine, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Aklillu E; Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institute, Stockholm, Sweden.
Engidawork E; Department of Pharmacology and Clinical Pharmacology, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2022 Jan 19; Vol. 17 (1), pp. e0262604. Date of Electronic Publication: 2022 Jan 19 (Print Publication: 2022).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Drug Therapy, Combination/*adverse effects
Glucose Metabolism Disorders/*epidemiology
HIV Infections/*metabolism
Adult ; Alkynes/therapeutic use ; Anti-HIV Agents/therapeutic use ; Antiretroviral Therapy, Highly Active/methods ; Atazanavir Sulfate/therapeutic use ; Benzoxazines/therapeutic use ; Blood Glucose/analysis ; Cross-Sectional Studies ; Cyclopropanes/therapeutic use ; Drug Combinations ; Drug Therapy, Combination/methods ; Ethiopia/epidemiology ; Female ; Glucose/metabolism ; Glucose Metabolism Disorders/virology ; HIV/pathogenicity ; Humans ; Insulin/metabolism ; Male ; Prevalence ; Ritonavir/therapeutic use
Czasopismo naukowe
Tytuł:
The bioequivalence of fixed-dose combination tablets of bisoprolol and ramipril and its drug-drug interaction potential.
Autorzy:
Sus J; Zentiva, k.s., Prague, Czech Republic.
Huguet J; Altasciences, Laval, Quebec, Canada.
Bosak J; Zentiva, k.s., Prague, Czech Republic.
Setnik B; Altasciences, Laval, Quebec, Canada.
Hauser T; Zentiva, k.s., Prague, Czech Republic.
Sicard E; Altasciences, Laval, Quebec, Canada.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2022 Jan; Vol. 15 (1), pp. 158-171. Date of Electronic Publication: 2021 Sep 08.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Drug Interactions*
Drug Therapy, Combination*
Therapeutic Equivalency*
Antihypertensive Agents/*administration & dosage
Bisoprolol/*administration & dosage
Ramipril/*administration & dosage
Adolescent ; Adult ; Female ; Humans ; Male ; Middle Aged ; Young Adult
Czasopismo naukowe
Tytuł:
Use of dual antiplatelet therapy following posterior ischemic stroke.
Autorzy:
Cupini LM; UOC Neurologia-Stroke Unit, Dipartimento d'Emergenza, Ospedale S. Eugenio, Roma. Italy. Electronic address: .
Bonaffini N; UOC Neurologia-Stroke Unit, Dipartimento d'Emergenza, Ospedale S. Eugenio, Roma. Italy.
Pokaż więcej
Źródło:
Journal of the neurological sciences [J Neurol Sci] 2022 Dec 15; Vol. 443, pp. 120486. Date of Electronic Publication: 2022 Nov 02.
Typ publikacji:
Letter
MeSH Terms:
Ischemic Stroke*/diagnostic imaging
Ischemic Stroke*/drug therapy
Brain Ischemia*/complications
Brain Ischemia*/drug therapy
Stroke*/complications
Stroke*/drug therapy
Ischemic Attack, Transient*/drug therapy
Humans ; Platelet Aggregation Inhibitors/therapeutic use ; Clopidogrel/therapeutic use ; Drug Therapy, Combination
Opinia redakcyjna
Tytuł:
Narrative review of brivaracetam for genetic generalized epilepsies.
Autorzy:
Lince-Rivera I; Child Neurology Resident, Universidad Militar Nueva Granada, Carrera 11 # 101 - 80, Bogotá, Colombia. Electronic address: .
Córdoba NM; Child Neurology Resident, Universidad Militar Nueva Granada, Carrera 11 # 101 - 80, Bogotá, Colombia.
la Rosa JSO; Child Neurologist, Epileptologist, Instituto Roosevelt, Bogotá, Colombia.
Pokaż więcej
Źródło:
Seizure [Seizure] 2022 Dec; Vol. 103, pp. 72-81. Date of Electronic Publication: 2022 Oct 21.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Anticonvulsants*/adverse effects
Epilepsy, Generalized*/drug therapy
Epilepsy, Generalized*/genetics
Humans ; Quality of Life ; Pyrrolidinones/adverse effects ; Treatment Outcome ; Drug Therapy, Combination
Czasopismo naukowe
Tytuł:
Effectiveness and tolerability of adjunctive perampanel in the treatment of pediatric patients with uncontrolled epilepsy: A retrospective, single-center, real-world study.
Autorzy:
Gao L; Department of Pediatrics, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou 450003, Henan, China. Electronic address: .
Shi L; Department of Pediatrics, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou 450003, Henan, China.
Liu Q; Department of Pediatrics, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou 450003, Henan, China.
Pokaż więcej
Źródło:
Epilepsy & behavior : E&B [Epilepsy Behav] 2022 Dec; Vol. 137 (Pt A), pp. 108961. Date of Electronic Publication: 2022 Oct 31.
Typ publikacji:
Journal Article
MeSH Terms:
Anticonvulsants*/adverse effects
Epilepsy*/drug therapy
Epilepsy*/chemically induced
Adolescent ; Humans ; Child ; Retrospective Studies ; Pyridones/adverse effects ; Treatment Outcome ; Drug Therapy, Combination
Czasopismo naukowe
Tytuł:
Pathogenicity and virulence of Mycobacterium leprae.
Autorzy:
Sugawara-Mikami M; Department of Clinical Laboratory Science, Faculty of Medical Technology, Teikyo University, Tokyo, Japan.; West Yokohama Sugawara Dermatology Clinic, Yokohama, Japan.
Tanigawa K; Department of Molecular Pharmaceutics, Faculty of Pharma-Science, Teikyo University, Tokyo, Japan.
Kawashima A; Department of Clinical Laboratory Science, Faculty of Medical Technology, Teikyo University, Tokyo, Japan.
Kiriya M; Department of Clinical Laboratory Science, Faculty of Medical Technology, Teikyo University, Tokyo, Japan.
Nakamura Y; Department of Molecular Pharmaceutics, Faculty of Pharma-Science, Teikyo University, Tokyo, Japan.
Fujiwara Y; Department of Clinical Laboratory Science, Faculty of Medical Technology, Teikyo University, Tokyo, Japan.
Suzuki K; Department of Clinical Laboratory Science, Faculty of Medical Technology, Teikyo University, Tokyo, Japan.
Pokaż więcej
Źródło:
Virulence [Virulence] 2022 Dec; Vol. 13 (1), pp. 1985-2011.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Mycobacterium leprae*/genetics
Leprosy*/drug therapy
Leprosy*/epidemiology
Animals ; Virulence ; Drug Therapy, Combination ; Leprostatic Agents
Czasopismo naukowe
Tytuł:
The Prescribing Practice for COPD: Relationship to Circadian Rhythm, Disease Severity, and Clinical Phenotype in the STORICO Observational Study.
Autorzy:
Incalzi RA; University Biomedical Campus of Rome, Via Alvaro del Portillo, 21, 00128, Rome, Italy. .
Blasi F; Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122, Milan, Italy.; Department of Pathophysiology and Transplantation, University of Milan, Via Francesco Sforza, 35, 20122, Milan, Italy.
Canonica GW; Personalized Medicine Asthma and Allergy Clinic, Humanitas University Humanitas Research Hospital Rozzano (Milan), Via Manzoni, 56, 20089, Rozzano (Milan), Italy.
Foschino MP; MAR4 Univ., D'Avanzo Hospital, Viale degli Aviatori, 1, 71122, Foggia, Italy.
Prediletto R; Pneumology, Institute of Clinical Physiology, National Research Council of Italy and Toscana G. Monasterio Foundation, Via Giuseppe Moruzzi, 1, 56124, Pisa, Italy.
Simoni L; Medineos Observational Research, Viale Virgilio 54/U, 41123, Modena, Italy.
Ori A; Medineos Observational Research, Viale Virgilio 54/U, 41123, Modena, Italy.
Giovannetti C; Laboratori Guidotti, Via Livornese, 897, 56122, Pisa, Italy.
Barsanti S; Laboratori Guidotti, Via Livornese, 897, 56122, Pisa, Italy.
Scichilone N; DIBIMIS, University of Palermo, Piazza delle Cliniche, 2, 90127, Palermo, Italy.
Pokaż więcej
Źródło:
Advances in therapy [Adv Ther] 2022 Dec; Vol. 39 (12), pp. 5582-5589. Date of Electronic Publication: 2022 Oct 11.
Typ publikacji:
Observational Study; Multicenter Study; Journal Article
MeSH Terms:
Adrenergic beta-2 Receptor Agonists*/therapeutic use
Pulmonary Disease, Chronic Obstructive*
Humans ; Circadian Rhythm ; Muscarinic Antagonists/therapeutic use ; Severity of Illness Index ; Phenotype ; Administration, Inhalation ; Bronchodilator Agents/therapeutic use ; Adrenal Cortex Hormones/therapeutic use ; Drug Therapy, Combination
Czasopismo naukowe
Tytuł:
The prospective multiple-centre randomized controlled clinical study of high-dose amoxicillin-proton pump inhibitor dual therapy for H. pylori infection in Sichuan areas.
Autorzy:
Shen C; Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Li C; Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Lv M; Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Dai X; Sichuan Provincial People's Hospital, Chengdu, China.
Gao C; Sichuan Provincial People's Hospital, Chengdu, China.
Li L; Sichuan Provincial People's Hospital, Chengdu, China.
Zhang Q; First People's Hospital of Liangshan Yi Autonomous Prefecture, Xichang, China.
Pan W; Sichuan University West China Hospital Tibet People's Government in Chengdu Office Branch, Chengdu, China.
Liu C; Sichuan University West China Hospital Tibet People's Government in Chengdu Office Branch, Chengdu, China.
Han S; Chengdu Medical College Second Affiliated Hospital, Chengdu, China.
Zhang Y; Chengdu Medical College Second Affiliated Hospital, Chengdu, China.
Ding S; People's Hospital of Deyang City, Deyang, China.
Deng H; People's Hospital of Deyang City, Deyang, China.
Yao Y; Suining Central Hospital, Suining, China.
Xu J; Suining Central Hospital, Suining, China.
Wei M; Sichuan Science City Hospital, Mianyang, China.
Shi H; Bazhong Central Hospital, Bazhong, China.
Yuan P; The Fourth People's Hospital of GuangYuan, GuangYuan, China.
Yang X; Chengdu Second People's Hospital, Chengdu, China.
Jian Y; Chengdu Second People's Hospital, Chengdu, China.
Shan J; Chengdu Third People's Hospital, Chengdu, China.
Liu Y; Chengdu Fifth People's Hospital, Chengdu, China.
Chen Z; The Second People's Hospital of Yibin, West China Hospital of Sichuan University, Yibin, China.
Deng X; People's Hospital of Leshan, Leshan, China.
Liu F; Leshan City Geriatric Hospital, Leshan, China.
Deng L; Leshan Sichuan Armed Police General Hospital, Leshan, China.
Zhong X; Leshan Sichuan Armed Police General Hospital, Leshan, China.
Li H; Pengzhou People's Hospital, Chengdu, China.
He S; Sichuan Anyue County People's Hospital, Ziyang, China.
Chen L; Sichuan Anyue County People's Hospital, Ziyang, China.
Liu G; Zigong Third People's Hospital, Zigong, China.
Xu H; Zigong Third People's Hospital, Zigong, China.
Zhong Y; First Peoples Hospital of Neijiang, Neijiang, China.
Shi H; The First People's Hospital of Ziyang, Ziyang, China.
Ren J; Wuhou District Third People's Hospital, Chengdu, China.
Pokaż więcej
Corporate Authors:
Multi-Center Clinical Research Collaboration Group of Sichuan Provincial H. pylori Scientific Group, Sichuan Provincial Medical Association
Źródło:
Annals of medicine [Ann Med] 2022 Dec; Vol. 54 (1), pp. 426-435.
Typ publikacji:
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Helicobacter Infections*/diagnosis
Helicobacter Infections*/drug therapy
Helicobacter pylori*
Amoxicillin/adverse effects ; Anti-Bacterial Agents ; Drug Therapy, Combination ; Humans ; Prospective Studies ; Proton Pump Inhibitors/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł:
REAP-HP survey 2020: Comparing the real-world practice and expectation in Helicobacter pylori eradication of the Taiwanese gastroenterologists in 2015 and 2020.
Autorzy:
Chuah YY; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Ping Tung Christian Hospital, Meiho University, Ping-Tung, Taiwan.
Wu DC; Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Chuah SK; Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Chen KY; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Renai Branch, Taipei City Hospital, Taipei, Taiwan.
Yang JC; Division of Gastroenterology, Department of Internal Medicine, Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan.
Lee CL; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Cathay General Hospital, Taipei, Taiwan.
Chen CL; Department of Medicine, Buddhist Tzu Chi General Hospital, Tzu Chi University, Hualien, Taiwan.
Shiu SI; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
Shie CB; Division of Gastroenterology, Department of Medicine, An Nan Hospital, China Medical University, Tainan, Taiwan.
Shih CA; Division of Gastroenterology, Department of Internal Medicine, Antai Medical Care Corporation, Antai Tian-Sheng Memorial Hospital, Meiho University, Ping-Tung, Taiwan.
Tsay FW; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, National Yang-Ming University, Kaohsiung, Taiwan.
Liu YH; Division of Gastroenterology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
Hsu PI; Division of Gastroenterology, Department of Medicine, An Nan Hospital, China Medical University, Tainan, Taiwan.
Pokaż więcej
Corporate Authors:
Taiwan Acid-related Disease & Microbiota Consortium (TARD-M)
Źródło:
Helicobacter [Helicobacter] 2022 Dec; Vol. 27 (6), pp. e12931. Date of Electronic Publication: 2022 Sep 25.
Typ publikacji:
Journal Article
MeSH Terms:
Helicobacter pylori*
Helicobacter Infections*/drug therapy
Gastroenterologists*
Humans ; Follow-Up Studies ; Motivation ; Anti-Bacterial Agents/therapeutic use ; Drug Therapy, Combination ; Surveys and Questionnaires ; Clarithromycin/therapeutic use ; Amoxicillin/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Impacts of dosing and drug withdrawal period on tacrolimus-based triple therapy in a non-human primate renal transplantation model.
Autorzy:
Naganuma Y; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
Maeda M; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan. Electronic address: .
Nakamura K; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
Fukahori H; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
Satake H; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
Murakami R; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
Hanaoka K; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
Higashi Y; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
Koyama H; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
Morokata T; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
Pokaż więcej
Źródło:
Transplant immunology [Transpl Immunol] 2022 Dec; Vol. 75, pp. 101704. Date of Electronic Publication: 2022 Aug 31.
Typ publikacji:
Journal Article
MeSH Terms:
Kidney Transplantation*
Animals ; Tacrolimus/therapeutic use ; Graft Rejection/drug therapy ; Graft Rejection/prevention & control ; Mycophenolic Acid/therapeutic use ; Immunosuppressive Agents/therapeutic use ; Immunosuppressive Agents/pharmacology ; Primates ; Calcineurin Inhibitors/therapeutic use ; Graft Survival ; Drug Therapy, Combination
Czasopismo naukowe
Tytuł:
Rheumatoid arthritis in a transman: A new case.
Autorzy:
García JCC; Unidad de Reumatología, Hospital Ernest Lluch Martín, Carretera de Sagunto-Burgos s/n. 50300, Calatayud, Zaragoza, Spain. Electronic address: .
Pokaż więcej
Źródło:
Seminars in arthritis and rheumatism [Semin Arthritis Rheum] 2022 Dec; Vol. 57, pp. 152093. Date of Electronic Publication: 2022 Sep 07.
Typ publikacji:
Case Reports; Letter; Comment
MeSH Terms:
Antirheumatic Agents*/therapeutic use
Breast Neoplasms*/drug therapy
Arthritis, Rheumatoid*/drug therapy
Arthritis, Rheumatoid*/surgery
Female ; Humans ; Drug Therapy, Combination ; Mastectomy ; Methotrexate/therapeutic use ; Treatment Outcome
Raport
Tytuł:
Efficacy of bismuth for antibiotic-resistant Helicobacter pylori strains eradication: A systematic review and meta-analysis.
Autorzy:
Han Z; Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Robot engineering laboratory for precise diagnosis and therapy of GI tumor, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Li Y; Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Robot engineering laboratory for precise diagnosis and therapy of GI tumor, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Kong Q; Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Robot engineering laboratory for precise diagnosis and therapy of GI tumor, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Liu J; Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Robot engineering laboratory for precise diagnosis and therapy of GI tumor, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Wang J; Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Robot engineering laboratory for precise diagnosis and therapy of GI tumor, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Wan M; Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Robot engineering laboratory for precise diagnosis and therapy of GI tumor, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Lin M; Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Robot engineering laboratory for precise diagnosis and therapy of GI tumor, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Lin B; Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Robot engineering laboratory for precise diagnosis and therapy of GI tumor, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Zhang W; Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Robot engineering laboratory for precise diagnosis and therapy of GI tumor, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Ding Y; Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Robot engineering laboratory for precise diagnosis and therapy of GI tumor, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Wang S; Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Robot engineering laboratory for precise diagnosis and therapy of GI tumor, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Mu Y; Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Robot engineering laboratory for precise diagnosis and therapy of GI tumor, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Duan M; Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Robot engineering laboratory for precise diagnosis and therapy of GI tumor, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Zuo X; Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Robot engineering laboratory for precise diagnosis and therapy of GI tumor, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Li YQ; Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Robot engineering laboratory for precise diagnosis and therapy of GI tumor, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Pokaż więcej
Źródło:
Helicobacter [Helicobacter] 2022 Dec; Vol. 27 (6), pp. e12930. Date of Electronic Publication: 2022 Sep 25.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article; Review
MeSH Terms:
Helicobacter pylori*
Helicobacter Infections*/drug therapy
Humans ; Bismuth/pharmacology ; Bismuth/therapeutic use ; Clarithromycin/therapeutic use ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Metronidazole/pharmacology ; Metronidazole/therapeutic use ; Levofloxacin/therapeutic use ; Drug Therapy, Combination ; Amoxicillin/therapeutic use ; Proton Pump Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł:
Triple Inhaler versus Dual Bronchodilator Therapy in COPD: Real-World Effectiveness on Mortality.
Autorzy:
Suissa S; Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital, Montreal, Canada.; Department of Epidemiology and Biostatistics, McGill University, Montreal, Canada.
Dell'Aniello S; Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital, Montreal, Canada.; Department of Epidemiology and Biostatistics, McGill University, Montreal, Canada.
Ernst P; Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital, Montreal, Canada.; Department of Epidemiology and Biostatistics, McGill University, Montreal, Canada.
Pokaż więcej
Źródło:
COPD [COPD] 2022 Dec; Vol. 19 (1), pp. 1-9. Date of Electronic Publication: 2021 Sep 21.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Pneumonia*/etiology
Pulmonary Disease, Chronic Obstructive*
Administration, Inhalation ; Adrenal Cortex Hormones/therapeutic use ; Adrenergic beta-2 Receptor Agonists/therapeutic use ; Bronchodilator Agents/therapeutic use ; Drug Therapy, Combination ; Humans ; Middle Aged ; Muscarinic Antagonists ; Nebulizers and Vaporizers
Czasopismo naukowe
Tytuł:
Uptake of hepatitis C virus treatment in a multi-state Medicaid population, 2013-2017.
Autorzy:
Clements KM; Commonwealth Medicine, University of Massachusetts Chan Medical School, Shrewsbury, Massachusetts, USA.
Kunte PS; Commonwealth Medicine, University of Massachusetts Chan Medical School, Shrewsbury, Massachusetts, USA.
Clark MA; Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Gurewich D; Center for Healthcare Organization and Implementation Research, VA Boston Health Care System Jamaica Plain Campus, Boston, Massachusetts, USA.
Greenwood BC; Commonwealth Medicine, University of Massachusetts Chan Medical School, Shrewsbury, Massachusetts, USA.
Sefton L; Commonwealth Medicine, University of Massachusetts Chan Medical School, Shrewsbury, Massachusetts, USA.
Pratt C; Commonwealth Medicine, University of Massachusetts Chan Medical School, Shrewsbury, Massachusetts, USA.
Person SD; Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Wessolossky MA; Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Pokaż więcej
Źródło:
Health services research [Health Serv Res] 2022 Dec; Vol. 57 (6), pp. 1312-1320. Date of Electronic Publication: 2022 May 04.
Typ publikacji:
Journal Article
MeSH Terms:
Hepatitis C, Chronic*/drug therapy
Hepatitis C*/drug therapy
United States ; Female ; Humans ; Male ; Hepacivirus ; Antiviral Agents/therapeutic use ; Medicaid ; Drug Therapy, Combination
Czasopismo naukowe
Tytuł:
Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer.
Autorzy:
Sumi T; Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, 38-3 Goryoukaku-Cho, Hakodate-shi, Hokkaido, 040-8611, Japan. .; Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan. .
Koshshino Y; Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, 38-3 Goryoukaku-Cho, Hakodate-shi, Hokkaido, 040-8611, Japan.; Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Sekikawa M; Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Nagahisa Y; Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Matsuura K; Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Shijubou N; Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Kamada K; Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Watanabe H; Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, 38-3 Goryoukaku-Cho, Hakodate-shi, Hokkaido, 040-8611, Japan.
Michimata H; Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, 38-3 Goryoukaku-Cho, Hakodate-shi, Hokkaido, 040-8611, Japan.; Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Nagayama D; Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, 38-3 Goryoukaku-Cho, Hakodate-shi, Hokkaido, 040-8611, Japan.; Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Tanaka Y; Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Yamada Y; Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, 38-3 Goryoukaku-Cho, Hakodate-shi, Hokkaido, 040-8611, Japan.
Chiba H; Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Pokaż więcej
Źródło:
Investigational new drugs [Invest New Drugs] 2022 Dec; Vol. 40 (6), pp. 1298-1305. Date of Electronic Publication: 2022 Oct 13.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/pathology
Antineoplastic Agents, Immunological*/adverse effects
Humans ; B7-H1 Antigen/metabolism ; Retrospective Studies ; Risk Factors ; Drug Therapy, Combination
Czasopismo naukowe
Tytuł:
Nrf2 regulates downstream genes by targeting miR-29b in severe asthma and the role of grape seed proanthocyanidin extract in a murine model of steroid-insensitive asthma.
Autorzy:
Qian Y; The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China.
Sun Y; The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China.
Chen Y; The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China.
Mao Z; The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China.
Shi Y; The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China.
Wu D; The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China.
Gu B; The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China.
Liu Z; The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China.
Zhang Q; The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China.
Pokaż więcej
Źródło:
Pharmaceutical biology [Pharm Biol] 2022 Dec; Vol. 60 (1), pp. 347-358.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Asthma/*drug therapy
Grape Seed Extract/*pharmacology
MicroRNAs/*genetics
NF-E2-Related Factor 2/*metabolism
Proanthocyanidins/*pharmacology
Adult ; Animals ; Anti-Asthmatic Agents/administration & dosage ; Anti-Asthmatic Agents/pharmacology ; Asthma/genetics ; Asthma/physiopathology ; Case-Control Studies ; Dexamethasone/administration & dosage ; Dexamethasone/pharmacology ; Disease Models, Animal ; Drug Therapy, Combination ; Female ; Gene Expression Regulation ; Grape Seed Extract/administration & dosage ; Humans ; Leukocytes, Mononuclear/drug effects ; Lipopolysaccharides ; Male ; Mice ; Mice, Inbred BALB C ; Middle Aged ; Ovalbumin ; Proanthocyanidins/administration & dosage ; Severity of Illness Index
Czasopismo naukowe
Tytuł:
The Immunobiogram, a novel in vitro diagnostic test to measure the pharmacodynamic response to immunosuppressive therapy in kidney transplant patients.
Autorzy:
Pascual J; Nephrology Department, Hospital del Mar, Institute Mar for Medical Research, Barcelona, Spain; Nephrology Department, Hospital 12 de Octubre, Madrid, Spain. Electronic address: .
Jiménez C; Nephrology Department, Hospital La Paz, Madrid, Spain.
Krajewska M; Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland.
Seron D; Nephrology Department, Hospital Vall d'Hebron, Barcelona, Spain.
Kotton CN; Transplant Infectious Diseases Division, Massachusetts General Hospital, Boston, MA, United States of America.
Portolés J; Nephrology Department, Hospital Puerta de Hierro, Madrid, Spain.
Witzke O; Department of Infectious Diseases, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Sorensen SS; Department of Nephrology, Rigshospitalet University Hospital Copenhagen, Denmark.
Andrés A; Nephrology Department, Hospital 12 de Octubre, Madrid, Spain.
Crespo M; Nephrology Department, Hospital del Mar, Institute Mar for Medical Research, Barcelona, Spain.
Paz-Artal E; Immunology Department, Hospital 12 de Octubre, Madrid, Spain.
Díez T; Biohope Scientific Solutions for Human Health, Madrid, Spain.
Ortega A; Biohope Scientific Solutions for Human Health, Madrid, Spain.
Portero I; Biohope Scientific Solutions for Human Health, Madrid, Spain.
Pokaż więcej
Źródło:
Transplant immunology [Transpl Immunol] 2022 Dec; Vol. 75, pp. 101711. Date of Electronic Publication: 2022 Sep 09.
Typ publikacji:
Observational Study; Multicenter Study; Journal Article
MeSH Terms:
Kidney Transplantation*/adverse effects
Humans ; Tacrolimus/therapeutic use ; Mycophenolic Acid/therapeutic use ; Graft Rejection/diagnosis ; Graft Rejection/drug therapy ; Diagnostic Tests, Routine ; Immunosuppressive Agents/adverse effects ; Cyclosporine/therapeutic use ; Immunosuppression Therapy ; Drug Therapy, Combination
Czasopismo naukowe
Tytuł:
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial.
Autorzy:
Goodall RL; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK. Electronic address: .
Meredith SK; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK.
Nunn AJ; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK.
Bayissa A; Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Bhatnagar AK; Rajan Babu Institute for Pulmonary Medicine & Tuberculosis, Delhi, India.
Bronson G; Vital Strategies, New York, NY, USA.
Chiang CY; Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; International Union against Tuberculosis and Lung Disease, Paris, France.
Conradie F; Empilweni TB Hospital, Eastern Cape, South Africa.
Gurumurthy M; Vital Strategies, Singapore.
Kirenga B; Makerere University Lung Institute, Mulago Hospital, Kampala, Uganda.
Kiria N; National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
Meressa D; St Peter's Tuberculosis Specialized Hospital and Global Health Committee, Addis Ababa, Ethiopia.
Moodliar R; Tuberculosis & HIV Investigative, Doris Goodwin Hospital, Pietermaritzburg, South Africa.
Narendran G; National Institute for Research in Tuberculosis, Chennai, India.
Ngubane N; King Dinuzulu Hospital Complex, Durban, South Africa.
Rassool M; Clinical HIV Research Unit, Helen Joseph Hospital, Department of Internal Medicine, University of the Witwatersrand, Johannesburg, South Africa.
Sanders K; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK.
Solanki R; B J Medical College, Ahmedabad, India.
Squire SB; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
Torrea G; Institute of Tropical Medicine, Antwerp, Belgium.
Tsogt B; Mongolian Tuberculosis Coalition, Ulaanbaatar, Mongolia.
Tudor E; Institute of Phthisiopneumology Chiril Draganiuc, Chisinau, Moldova.
Van Deun A; Institute of Tropical Medicine, Antwerp, Belgium.
Rusen ID; Vital Strategies, New York, NY, USA.
Pokaż więcej
Corporate Authors:
STREAM study collaborators
Źródło:
Lancet (London, England) [Lancet] 2022 Nov 26; Vol. 400 (10366), pp. 1858-1868. Date of Electronic Publication: 2022 Nov 08.
Typ publikacji:
Randomized Controlled Trial; Multicenter Study; Journal Article
MeSH Terms:
Tuberculosis, Multidrug-Resistant*/drug therapy
HIV Infections*/epidemiology
Humans ; Rifampin/therapeutic use ; CD4 Lymphocyte Count ; Drug Therapy, Combination
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Prześlij opinię

Twoje opinie są dla nas bardzo ważne i mogą być niezwykle pomocne w pokazaniu nam, gdzie możemy dokonać ulepszeń. Bylibyśmy bardzo wdzięczni za poświęcenie kilku chwil na wypełnienie krótkiego formularza.

Formularz